CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes

Life Sciences

Volumn 67, Issue 24, 2000, Pages 2913-2920

  Tateishi, Tomonori ^a,c   Watanabe, Minoru ^a   Kumai, Toshio ^a   Tanaka, Masami ^a   Moriya, Hitonobu ^a   Yamaguchi, Susumu ^a   Satoh, Tetsuo ^b   Kobayashi, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Biomedical Research Institute   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Bromperidol; CYP3A; Haloperidol; Human liver microsomes

Indexed keywords

BROMPERIDOL; CYTOCHROME P450 3A; FURAFYLLINE; HALOPERIDOL; NIFEDIPINE; PROADIFEN; QUINIDINE; RECOMBINANT ENZYME; TROLEANDOMYCIN;

ALKYLATION; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; OXIDATION;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0034602294     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)00874-2     Document Type: Article

References (29)

1. Pharmacokinetics of haloperidol
2. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses
3. Bromperidol, a new butyrophenone neuroleptic: A review
4. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia
5. Monitoring of serum haloperidol
6. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
7. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
8. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol
9. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation
10. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol
11. Liver damage induced by bile duct ligation affects CYP isoenzymes differently in rats
12. Protein measurement with the Folin Phenol reagent
13. Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics is rats
14. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drag metabolism
15. Molecular non-genetic biomarkers related to Fenarimol cocarcinogenesis: Organ- and sex-specific CYP induction in rat
16. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes
17. The CYP3A family
18. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man
19. The CYP2D family
20. Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase)
21. Effect of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
22. Coadministration of fluvoxamine increases serum concentrations of haloperidol
23. Elevation of plasma concentration of haloperidol after the addition of fluvoxaime
24. Dose-dependent inhibition of CYP1A2, CYP2C 19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
25. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping
26. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro
27. Interaction between carbamazepine and bromperidol
28. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism
29. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylafion via CYP2C19